The Effect of genotypes in doners and recipients on the Pharmacokinetics of Tacrolimus in Liver Transplantation Recipients

The effect of genotypes on the Pharmacokinetics of Tacrolimus

Status

Active, not recruiting

Phases

Phase 4

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR-ONC-11001702

Enrollment

Unknown

Registered

2011-11-09

Start date

2010-02-09

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Transplantation

Interventions

PK group:To mesuar the pharmacokinetics of tacrolimus at the 14 day after transplantation

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: The Chinese recipients who was the first time to accept the liver trnasplantation in Tianjin First Central Hospital, and with no other transplantation; 18-65 years old; both men and women;accept FK506+MMF+Pred as the primary immunosuppressant.

Exclusion criteria

Exclusion criteria: The patients who with anorexia nervosa, malabsorption syndrome,gestrointestinal removoval surgery which will influence the absorbtion of Fk506 patients were excluded.

Design outcomes

Primary

Measure	Time frame
C0;pharmacokinetics of tacrolimus;	—

Countries

China

Contacts

Public ContactZhang Yi

wing_zh1821@sina.com+86 13512990209

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026